What is Major Depressive Disorder?
Major Depressive Disorder (MDD), also referred as depression, is a serious medical illness that disrupts a person’s mood, behavior, thought processes, apart from degrading the physical health.
How Major Depressive Disorder affected population?
Major Depressive Disorder Epidemiology
- The most prevalent cases of Major Depressive Disorder (MDD) were recorded in the United States.
- Among the European 5 countries, France had highest prevalent population of Major Depressive Disorder (MDD), followed by Germany and Spain. On the other hand, the United Kingdom had the lowest prevalent population of Major Depressive Disorder (MDD)
- The third most prevalent cases of Major Depressive Disorder (MDD) in 7MM were recorded in Japan.
To know more, request sample pages of Major Depressive Disorder Market @ https://www.delveinsight.com/report-store/major-depressive-disorder-market
Major Depressive Disorder Market Outlook
The various major American and European guidelines for the treatment of depression provide similar basic principles of treatment, which include individualizing the treatment plan, preparing the patient for potential long-term treatment, providing measurement-based care, and treating to remission.
The new evidence-based guideline summarizes recommendations on the use of antidepressants and other drug therapies; psychotherapy, including cognitive behavior therapy; and Electroconvulsive Therapy (ECT).
Apart from therapies, companies are also focussed on the development of technologies that could further assist in the better management of the disease. BrainsWay’s Deep TMS received FDA clearance in 2018 to treat MDD. Deep TMS works by utilizing a magnetic field that manages to directly reach wider and deeper brain regions, regulating the neural activity of brain structures related to depression – specifically the dorsolateral prefrontal cortex (DLPFC).
What are the Major Depressive Disorder Market Drivers?
Introduction of new pathway, increasing awareness on depression, and increasing spending on branded drugs are the present Major Depressive Disorder market drivers.
What are the Major Depressive Disorder Market Barriers?
Challenges in diagnoses, economic burden, and generic products are the Major Depressive Disorder market barriers.
Which are the leading companies in Major Depressive Disorder market?
The emerging treatment options in Major Depressive Disorder Market Landscape aim to improve the responses which are inadequate with respect to standard antidepressant therapies. Companies such as Axsome Therapeutics, SAGE Therapeutics, J&J/ Minerva Neurosciences, Intra-Cellular Therapies, and others are developing the therapies to transform the Major Depressive Disorder treatment scenario.
Table of contents
1. Key Insights
2. Executive Summary of Major Depressive Disorder
3. Competitive Intelligence Analysis for Major Depressive Disorder
4. Major Depressive Disorder: Market Overview at a Glance
4.1. Major Depressive Disorder Total Market Share (%) Distribution in 2017
4.2. Major Depressive Disorder Total Market Share (%) Distribution in 2030
5. Major Depressive Disorder: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Major Depressive Disorder Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Major Depressive Disorder Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Major Depressive Disorder Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Major Depressive Disorder Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Major Depressive Disorder Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Major Depressive Disorder Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Major Depressive Disorder Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Major Depressive Disorder Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Major Depressive Disorder Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Major Depressive Disorder Treatment and Management
8.2. Major Depressive Disorder Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Major Depressive Disorder Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Major Depressive Disorder: Seven Major Market Analysis
13.1. Key Findings
13.2. Major Depressive Disorder Market Size in 7MM
13.3. Major Depressive Disorder Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Major Depressive Disorder Total Market Size in the United States
15.1.2. Major Depressive Disorder Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Major Depressive Disorder Total Market Size in Germany
15.3.2. Major Depressive Disorder Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Major Depressive Disorder Total Market Size in France
15.4.2. Major Depressive Disorder Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Major Depressive Disorder Total Market Size in Italy
15.5.2. Major Depressive Disorder Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Major Depressive Disorder Total Market Size in Spain
15.6.2. Major Depressive Disorder Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Major Depressive Disorder Total Market Size in the United Kingdom
15.7.2. Major Depressive Disorder Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Major Depressive Disorder Total Market Size in Japan
15.8.3. Major Depressive Disorder Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Major Depressive Disorder
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request sample pages for more information on Major Depressive Disorder Market @ https://www.delveinsight.com/sample-request/major-depressive-disorder-market
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/